



June 29, 2023

## News Release

Company name: TMS Co., Ltd.  
Name of representative: Takuro Wakabayashi, Chief Executive Officer  
(Securities code: 4891; Growth Market)

### **TMS Co., Ltd. entered into Joint Research Agreement with the Microbial Chemistry Research Foundation**

TMS Co., Ltd. (the “Company”) announces today that the Company has completed the process for entering into a Joint Research Agreement with the Microbial Chemistry Research Foundation (the “MCRF”) on compound discovery. The agreement was made effective on June 23, 2023.

As part of its efforts towards pipeline expansion, the Company is searching for new drug candidates utilizing multiple approaches, including AI-based compound generation. In the Joint Research with the MCRF, the Company intends to discover naturally derived compounds against the targets of Company’s interest by screening the microorganism library as well as compound libraries provided by the MCRF. The Company expects that the Joint Research may contribute to expansion of its pipeline in the future.

Since this initiative is in the exploratory stage, the impact on the Company's business performance for the current fiscal year is expected to be minimal.

#### **About MCRF**

The foundation was established in 1958 from the proceeds of the patent of Kanamycin discovered by Dr. Hamao Umezawa. The foundation promotes research activities with the aim of conducting research on microorganisms, discovering a wide range of beneficial substances, and developing and utilizing them to contribute to the prevention and treatment of disease, and thereby promote the health and welfare of the people. In particular, the foundation focuses on the development and research of novel biologically active substances (antibiotics, anti-cancer drugs, and other drugs for the treatment of diseases, etc.) by utilizing its own natural product library and strain library. In the Nature Index 2018 Japan, the foundation was ranked as the No. 1 Japanese research institute which published the highest percentage of high-quality scientific papers in the field of natural science. For more information about the foundation, please visit the website at <https://www.bikaken.or.jp/>.

#### **About TMS Co., Ltd.**

TMS is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases to address medical unmet needs. The Company’s pipeline consists of a family of small compounds called SMTPs (Stachybotrys microspora triprenyl phenols) derived from a fungus. The lead pipeline compound, TMS-007, is indicated for the treatment of acute ischemic stroke. It demonstrated efficacy and safety in the completed Phase 2 study and was acquired by Biogen in 2021. Another SMTP compound, TMS-008, is under development for acute kidney injury and other potential indications. In addition, the Company is exploring new pipeline products by focusing on early-stage seeds from academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit <https://www.tms-japan.co.jp/>.

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Investor and Media Contact:  
[ir@tms-japan.co.jp](mailto:ir@tms-japan.co.jp)

End